Our pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism, currently preparing for Phase 3 development, and a growing obesity portfolio that includes MBX 4291 in Phase 1 development, MBX 5765, a next-generation amycretin prodrug designed for once-monthly-dosing, as well as MBX 6180, a GLP/GIP/GCGR triple agonist prodrug for once monthly dosing; all of which optimize our PEP platform. The Director will serve as a key cross-functional leader, partnering closely with Clinical Development, Medical, Biometrics, Regulatory, Clinical Pharmacology, Translational Medicine, and external vendors to advance innovative peptide-based therapies for patients with obesity and related metabolic disorders.